Breast Cancer Clinical Trial
Official title:
Age-related Changes in the Immune System and Their Impact on Elderly Breast Cancer
This research project aims to study this intriguing relationship between ageing and breast cancer biology, and more specifically the changes that occur within the tumor microenvironment with increasing age. Furthermore, it will focus on the link between these microenvironmental changes and organismal ageing (as measured by chronological age, geriatric evaluation of elderly patients, and circulating biomarkers of ageing), since it seems logical that age-related changes in the stromal part of a tumor (fibroblasts, immune cells, endothelial cells, fatty cells, …i.e. host cells) are due to the ageing process of the entire body. Most particularly, the amount and type of infiltrating immune cells might reflect the degree of immunosenescence of the host. More and more research points out the crucial role of the immune system in tumorigenesis and progression, and, at the same time, the immune system is one of the most affected components in the process of ageing. .
Despite the high relevance of ageing/immunosenescence and frailty in oncogeriatric practice,
immuno-senescence markers have so far not been considered in concert with clinical tumor
characteristics and the profile of tumor infiltrating leukocytes. In the proposed project,
the investigators will examine immunosenescence markers in blood and characterize the
leukocyte infiltrate in the tumor microenvironment in the setting of elderly breast cancer.
The main goal of this project is thus to investigate the relation and interaction between
the following 3 aspects:
(i) immune status of the host: chronological age and immunosenescence in peripheral blood;
(ii) tumor microenvironment: local immune response (evaluated via assessment of the amount
and nature of tumor infiltrating leukocytes [TIL]); (iii) clinical tumor characteristics:
tumor size, grade, receptor status, lymph node involvement.
To realize this project, the investigators will set up a prospective clinical study
comprising three distinct age categories of breast cancer patients and integrating a variety
of immunosenescence markers. Different specific manifestations of immune system ageing will
be studied : age-related pro-inflammatory status (inflammageing), increased expression of
the senescence marker p16INK4a in T lymphocytes, shifts in subset composition of the PBMC
pool, age-associated changes in expression of immune-related genes in PBMC and altered
abundance of specific ageing-related plasma microRNAs.
At the tumor microenvironmental level, the leukocyte infiltrate will be studied in detail.
The profile of tumor-infiltrating immune cells will be compared between the distinct age
groups and will be correlated to systemic markers of ageing/immunosenescence (in blood) and
tumor biology, most particularly lymph node involvement.
Concrete research questions:
- How are the different immunosenescence markers (i.e. subset profile of PBMC,
pro-inflammatory markers in plasma, lymphocyte senescence as evidenced by p16INK4a
expession in T lymphocytes, expression of immune-related genes in PBMC and abundance of
ageing-related circulating microRNAs) correlated with each other and with the patient's
calendar age?
- Does the local immune response in the tumor (amount and nature of TIL) correlate with
the different immunosenescence markers?
- Is there a relationship between tumor biology, most particularly lymph node
involvement, and the local immune response in the tumor ?
With this study, the investigators intend to improve our fundamental understanding of
age-related changes in general immune status and tumor-specific immune responses and their
impact on tumor progression. This may add to recent advances in newly emerging therapeutic
strategies, such as immune-related approaches. Due to recent advances in biology and
genomics, it has become possible to personalize an individual's cancer treatment based on
molecular tumor characteristics. In the elderly, however, host factors also become
increasingly important and may influence both tumor behavior/progression and therapy
tolerance/response. Therefore, a better understanding of the biological mechanisms
underlying ageing/immunosenescence, its association with cancer and the potential
prognostic/predictive information that the patient's ageing/immunosenescence profile can
provide is mandatory.
;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
| Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
| Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
| Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
| Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
| Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
| Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
| Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
| Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
| Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
| Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |